Infinity Pharmaceuticals, Inc. (NasdaqGS: INFI) Loss Submission Form

Kuznicki Law is investigating the proposed merger of Infinity Pharmaceuticals, Inc. (the “Company”) (NasdaqGS: INFI) with MEI Pharma, Inc. (NasdaqCM: MEIP). Under the terms of the proposed transaction, Infinity shareholders will end up owning 42.0% of the outstanding equity of the combined company. Kuznicki Law is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger undervalues the Company.